Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo

Neurobiology of Disease

Volumn 33, Issue 2, 2009, Pages 182-192

  Meurers, B H ^a   Zhu, C ^a   Fernagut, P O ^a   Richter, F ^a   Hsia, Y C ^a   Fleming, S M ^a   Oh, M ^b   Elashoff, D ^b   DiCarlo, C D ^c   Seaman, R L ^d   Chesselet, M F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BASAL GANGLION; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXPLORATORY BEHAVIOR; GENE EXPRESSION; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ANIMALS; BODY WEIGHT; CELL DEATH; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; EXPLORATORY BEHAVIOR; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION; GENE EXPRESSION PROFILING; MALE; MITOCHONDRIA; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RATS; RNA, MESSENGER; ROTENONE; SUBSTANTIA NIGRA; TRANSCRIPTIONAL ACTIVATION;

EID: 58149512092     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.10.001     Document Type: Article

References (65)

1. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 1 (2002) 317-324
2. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., and Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38 5 (2006) 515-517
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 12 (2000) 1301-1306
4. Bonaventure P., Guo H., Tian B., Liu X., Bittner A., Roland B., Salunga R., Ma X.J., Kamme F., Meurers B., Bakker M., Jurzak M., Leysen J.E., and Erlander M.G. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res. 943 1 (2002) 38-47
5. Braak H., Rüb U., Gai W.P., and Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. 110 5 (2003) 517-536
6. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 3 (2002) 615-624
7. Cantuti-Castelvetri I., Keller-McGandy C., Bouzou B., Asteris G., Clark T.W., Frosch M.P., and Standaert D.G. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 26 3 (2007) 606-614
8. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., and Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447 7148 (2007) 1081-1086
9. Chung J.W., Jeon J.H., Yoon S.R., and Choi I. Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J. Dermatol. 33 10 (2006) 662-669
10. Doran B., Gherbesi N., Hendricks G., Flavell R.A., Davis R.J., and Gangwani L. Deficiency of the zinc finger protein ZPR1 causes neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 103 19 (2006) 7471-7475
11. Ducker C.E., Upson J.J., French K.J., and Smith C.D. Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol.Cancer Res. 3 8 (2005) 463-476
12. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23 8 (2004) 1539-1548
13. Efron B., and Tibshirani R. Empirical bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 23 1 (2002) 70-86
14. Fan G.C., Chu G., Mitton B., Song Q., Yuan Q., and Kranias E.G. Small heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced cardiac apoptosis. Circ. Res. 94 11 (2004) 1474-1482
15. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 5 (1991) 2283-2301
16. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., and Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 187 2 (2004) 418-429
17. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., and Bronfman M. Peroxisome proliferator-activated receptor {gamma} Up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282 51 (2007) 37006-37015
18. Galiana E., Vernier P., Dupont E., Evrard C., and Rouget P. Identification of a neural-specific cDNA, NPDC-1, able to down-regulate cell proliferation and to suppress transformation. Proc. Natl. Acad. Sci. U. S. A. 92 5 (1995) 1560-1564
19. Grünblatt E., Mandel S., Maor G., and Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78 1 (2001) 1-12
20. Grünblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., Li J., Ravid R., Roggendorf W., Riederer P., and Youdim M.B. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111 12 (2004) 1543-1573
21. Gu G., Deutch A.Y., Franklin J., Levy S., Wallace D.C., and Zhang J. Profiling genes related to mitochondrial function in mice treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem. Biophys. Res. Commun. 308 1 (2003) 197-205
22. Hammarsund M., Lerner M., Zhu C., Merup M., Jansson M., Gahrton G., Kluin-Nelemans H., Einhorn S., Grandér D., Sangfelt O., and Corcoran M. Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia. Hum. Mol. Genet. 13 23 (2004) 2925-2936
23. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 6180 (1988) 345-348
24. Höglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 3 (2003) 491-502
25. Joguchi A., Otsuka I., Minagawa S., Suzuki T., Fujii M., and Ayusawa D. Overexpression of VDUP1 mRNA sensitizes HeLa cells to paraquat. Biochem. Biophys. Res. Commun. 293 1 (2002) 293-297
26. Junn E., Han S.H., Im J.Y., Yang Y., Cho E.W., Um H.D., Kim D.K., Lee K.W., Han P.L., Rhee S.G., and Choi I. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J. Immunol. 164 12 (2000) 6287-6295
27. Kamme F., Zhu J., Luo L., Yu J., Tran D.T., Meurers B., Bittner A., Westlund K., Carlton S., and Wan J. Single-cell laser-capture microdissection and RNA amplification. Methods Mol. Med. 99 (2004) 215-223
28. Katayama Y., Sakai A., Oue N., Asaoku H., Otsuki T., Shiomomura T., Masuda R., Hino N., Takimoto Y., Imanaka F., Yasui W., and Kimura A. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br. J. Haematol. 120 2 (2003) 223-234
29. Kolluri S.K., Balduf C., Hofmann M., and Göttlicher M. Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res. 61 23 (2001) 8534-8539
30. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., and Cicchetti F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J. 18 6 (2004) 717-719
31. Li M., David C., Kikuta T., Somogyvari-Vigh A., and Arimura A. Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J. Mol. Neurosci. 27 1 (2005) 91-105
32. Li X., Baumgart E., Dong G.X., Morrell J.C., Jimenez-Sanchez G., Valle D., Smith K.D., and Gould S.J. PEX11alpha is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated peroxisome proliferation. Mol. Cell. Biol. 22 23 (2002) 8226-8240
33. Liss B., Haeckel O., Wildmann J., Miki T., Seino S., and Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 8 12 (2005) 1742-1751
34. Lu Y., Selvakumar P., Ali K., Shrivastav A., Bajaj G., Resch L., Griebel R., Fourney D., Meguro K., and Sharma R.K. Expression of N-myristoyltransferase in human brain tumors. Neurochem. Res. 30 1 (2005) 9-13
35. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schapira A.H., and Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 2 (1992) 333-342
36. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., Kaysser-Kranich T.M., Sendera T.J., Palaniappan C., and Federoff H.J. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 24 34 (2004) 7445-7454
37. Miller R.M., Kiser G.L., Kaysser-Kranich T.M., Lockner R.J., Palaniappan C., and Federoff H.J. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis. 21 2 (2006) 305-313
38. Minn A.H., Hafele C., and Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146 5 (2005) 2397-2405
39. Morris M.R., Gentle D., Abdulrahman M., Maina E.N., Gupta K., Banks R.E., Wiesener M.S., Kishida T., Yao M., The B., Lati F., and Maher E.R. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 65 11 (2005) 4598-4606
40. Nishinaka Y., Nishiyama A., Masutani H., Oka S., Ahsan K.M., Nakayama Y., Ishii Y., Nakamura H., Maeda M., and Yodoi J. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res. 64 4 (2004) 1287-1292
41. Nishiyama A., Matsui M., Iwata S., Hirota K., Masutani H., Nakamura H., Takagi Y., Sono H., Gon Y., and Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 274 31 (1999) 21645-21650
42. Oh-hashi K., Naruse Y., Amaya F., Shimosato G., and Tanaka M. Cloning and characterization of a novel GRP78-binding protein in the rat brain. J. Biol. Chem. 278 12 (2003) 10531-10537
43. Ohta S., Lai E.W., Pang A.L., Brouwers F.M., Chan W.Y., Eisenhofer G., de Krijger R., Ksinantova L., Breza J., Blazicek P., Kvetnansky R., Wesley R.A., and Pacak K. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer 114 1 (2005) 139-143
44. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., and Vogelstein B. A model for p53-induced apoptosis. Nature 389 6648 (1997) 300-305
45. Qi X., Hosoi T., Okuma Y., Kaneko M., and Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66 4 (2004) 899-908
46. Roberts R.A. Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Ann. N. Y. Acad. Sci. 804 (1996) 588-611
47. Ryu E.J., Angelastro J.M., and Greene L.A. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol. Dis. 18 1 (2004) 54-74
48. Sakurai T., Itoh K., Higashitsuji H., Nonoguchi K., Liu Y., Watanabe H., Nakano T., Fukumoto M., Chiba T., and Fujita J. Cirp protects against tumor necrosis factor-alpha-induced apoptosis via activation of extracellular signal-regulated kinase. Biochim. Biophys. Acta. 1763 3 (2006) 290-295
49. Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 333 8649 (1989) 1269
50. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 3 (1990) 823-827
51. Schrader M., Reuber B.E., Morrell J.C., Jimenez-Sanchez G., Obie C., Stroh T.A., Valle D., Schroer T.A., and Gould S.J. Expression of PEX11beta mediates peroxisome proliferation in the absence of extracellular stimuli. J. Biol. Chem. 273 45 (1998) 29607-29614
52. Schrader M., and Fahimi H.D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta 1763 12 (2006) 1755-1766
53. Schulze P.C., Yoshioka J., Takahashi T., He Z., King G.L., and Lee R.T. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J. Biol. Chem. 279 29 (2004) 30369-30374
54. Selvakumar P., Smith-Windsor E., Bonham K., and Sharma R.K. N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system. FEBS Lett. 580 8 (2006) 2021-2026
55. Selvakumar P., and Sharma R.K. Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer. Int. J. Mol. Med. 19 5 (2007) 823-827
56. Selvakumar P., Lakshmikuttyamma A., Charavaryamath C., Singh B., Tuchek J., and Sharma R.K. Expression of myristoyltransferase and its interacting proteins in epilepsy. Biochem. Biophys. Res. Commun. 335 4 (2007) 1132-1139
57. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanisms of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 34 (2003) 10756-10764
58. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 1 (2003) 9-16
59. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P., Davis R.E., and Parker Jr. W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40 4 (1996) 663-671
60. Wakabayashi T., Kosaka J., and Oshika T. JNK inhibitory kinase is up-regulated in retinal ganglion cells after axotomy and enhances BimEL expression level in neuronal cells. J. Neurochem. 95 2 (2005) 526-536
61. Wu Z., Irizarry R.A., Gentleman R., Murillo F.M., and Spencer F. A model based background adjustment for oligonucleotide expression arrays (2003), Technical Report, John Hopkins University, Department of Biostatistics, Working Papers, Baltimore, MD
62. Xue L., Zhou B., Liu X., Qiu W., Jin Z., and Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 63 5 (2003) 980-986
63. Yew E.H., Cheung N.S., Choy M.S., Qi R.Z., Lee A.Y., Peng Z.F., Melendez A.J., Manikandan J., Koay E.S., Chiu L.L., Ng W.L., Whiteman M., Kandiah J., and Halliwell B. Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J. Neurochem. 94 4 (2005) 943-956
64. Yoshida T., Nakamura H., Masutani H., and Yodoi J. The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann. N. Y. Acad. Sci. 1055 (2005) 1-12
65. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., and Chesselet M.F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478 4 (2004) 418-426